BioWorld Asia

Oct. 5, 2011

Creabilis Raises $20M in Series B to Advance Psoriasis Drug

Creabilis S.A. raised €15 million (US$20 million) in a Series B round to advance a pipeline of three compounds in development for dermatology, inflammation and pain indications. (BioWorld International) Read More

European Biomedical Research Lags U.S. in Quality, Spending

Proposed Leukemia Therapy Acts Through Epigenetics

Galapagos Bags Potential $346M Cancer R&D Deal with Servier

Prosonix Brings in £11.4M to Back Smart Particle Technology

Lundbeck Gets Dibs on Proximagen CNS Products

$54M EC Vaccine Research Initiative to Kick Off in Siena

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 3, 2026

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent

BioWorld Science

Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...